Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo (full – 2010) http/jnm.snmjournals.org/cgi/content/full/51/9/1413
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC2848893/?toolubmed
Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC2931573/?toolubmed
Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3659808/
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (link to PDF – 2010) http/www.mdpi.com/1424-8247/3/8/2689
The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. (abst – 2010) http/www.ncbi.nlm.nih.gov/pubmed/20353779
Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. (abst – 2010) http/www.unboundmedicine.com/medline/ebm/record/20600638/abstract/Behavioural_and_molecular_consequences_of_chronic_ cannabinoid_treatment_in_Huntington%27s_disease_tr ansgenic_mice_
Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study (news – 2010) http/www.news-medical.net/news/20100807/Drugs-that-reduce-activity-of-ABDH6-enzyme-can-preventbrain-damage-Study.aspx
Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
Prospects for cannabinoid therapies in basal ganglia disorders. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3165947/
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. (full – 2011) http/brain.oxfordjournals.org/content/134/1/119.long
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21674569
Worsening of Huntington disease phenotype in CB1 receptor knockout mice. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21406230/abstract/Worsening_of_Huntington_disease_phenotype_in_CB1_r eceptor_knockout_mice_
Metabolic and Type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21459091/abstract/Metabolic_and_Type_1_cannabinoid_receptor_imaging_ of_a_transgenic_rat_model_in_the_early_phase_of_Hu ntington_disease_
Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/22207189
Cannabinoid modulation of neuroinflammatory disorders. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3386505/
The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription (full - 2012) http/onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02175.x/full
Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB(1) and CB(2) Receptors. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3382456/
Review article: The endocannabinoid system in normal and pathological brain ageing (full – 2012) http/rstb.royalsocietypublishing.org/content/367/1607/3326.full?sid=161e7b36-5055-448b-962e-697c782e901d
Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3753072/
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3579248/
Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3699342/
Cannabinoids: Novel Medicines for the Treatment of Huntington's Disease. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22280340
The Influence of Cannabinoids on Generic Traits of Neurodegeneration. (full – 2013) http/onlinelibrary.wiley.com/doi/10.1111/bph.12492/full
In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system. (full – 2013) http/onlinelibrary.wiley.com/doi/10.1111/febs.12329/full
Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23602984
CNR1 variation is associated with the age at onset in Huntington disease. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23747361
Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23829360
The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24360910
The endocannabinoid system: a putative role in neurodegenerative diseases. (full – 2014) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC4070159/
Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24603212
Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24978314
Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/25018107
Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/25123645
The therapeutic efficacy of cannabinoid receptor type 1 ligands in Huntington's disease may depend on their functional selectivity (abst – 2014) http/www.fasebj.org/content/28/1_Supplement/846.6.abstract?sid=467bb529-0ecc-4ddc-af27-3f56f520a102
Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25134728
Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/25252936
Differential effects of delayed aging on phenotype and striatal pathology in a murine model of huntington disease (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/25411494
Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets (full - 2015) http://onlinelibrary.wiley.com/doi/1.../prp2.104/full
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC2848893/?toolubmed
Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC2931573/?toolubmed
Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3659808/
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (link to PDF – 2010) http/www.mdpi.com/1424-8247/3/8/2689
The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. (abst – 2010) http/www.ncbi.nlm.nih.gov/pubmed/20353779
Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. (abst – 2010) http/www.unboundmedicine.com/medline/ebm/record/20600638/abstract/Behavioural_and_molecular_consequences_of_chronic_ cannabinoid_treatment_in_Huntington%27s_disease_tr ansgenic_mice_
Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study (news – 2010) http/www.news-medical.net/news/20100807/Drugs-that-reduce-activity-of-ABDH6-enzyme-can-preventbrain-damage-Study.aspx
Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/
Prospects for cannabinoid therapies in basal ganglia disorders. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3165947/
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. (full – 2011) http/brain.oxfordjournals.org/content/134/1/119.long
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/21674569
Worsening of Huntington disease phenotype in CB1 receptor knockout mice. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21406230/abstract/Worsening_of_Huntington_disease_phenotype_in_CB1_r eceptor_knockout_mice_
Metabolic and Type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21459091/abstract/Metabolic_and_Type_1_cannabinoid_receptor_imaging_ of_a_transgenic_rat_model_in_the_early_phase_of_Hu ntington_disease_
Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. (abst – 2011) http/www.ncbi.nlm.nih.gov/pubmed/22207189
Cannabinoid modulation of neuroinflammatory disorders. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3386505/
The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription (full - 2012) http/onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02175.x/full
Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB(1) and CB(2) Receptors. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3382456/
Review article: The endocannabinoid system in normal and pathological brain ageing (full – 2012) http/rstb.royalsocietypublishing.org/content/367/1607/3326.full?sid=161e7b36-5055-448b-962e-697c782e901d
Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3753072/
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3579248/
Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3699342/
Cannabinoids: Novel Medicines for the Treatment of Huntington's Disease. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22280340
The Influence of Cannabinoids on Generic Traits of Neurodegeneration. (full – 2013) http/onlinelibrary.wiley.com/doi/10.1111/bph.12492/full
In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system. (full – 2013) http/onlinelibrary.wiley.com/doi/10.1111/febs.12329/full
Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23602984
CNR1 variation is associated with the age at onset in Huntington disease. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23747361
Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23829360
The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24360910
The endocannabinoid system: a putative role in neurodegenerative diseases. (full – 2014) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC4070159/
Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24603212
Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24978314
Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/25018107
Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/25123645
The therapeutic efficacy of cannabinoid receptor type 1 ligands in Huntington's disease may depend on their functional selectivity (abst – 2014) http/www.fasebj.org/content/28/1_Supplement/846.6.abstract?sid=467bb529-0ecc-4ddc-af27-3f56f520a102
Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25134728
Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/25252936
Differential effects of delayed aging on phenotype and striatal pathology in a murine model of huntington disease (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/25411494
Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets (full - 2015) http://onlinelibrary.wiley.com/doi/1.../prp2.104/full